Trial Profile
The effect of pioglitazone and rosiglitazone on atherosclerotic and inflammatory markers in patients with metabolic syndrome: a prospective, randomized, open-label, crossover trial
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Pioglitazone (Primary) ; Rosiglitazone (Primary)
- Indications Metabolic syndrome
- Focus Pharmacodynamics
- 26 Jun 2007 Status changed from recruiting to completed.
- 12 Dec 2006 New trial record.